September 26, 2011
GNI Group Ltd., an international biopharmaceutical company, announced on September 22 that its Chinese subsidiary Shanghai Genomics received on the same day a new drug certificate for the treatment of idiopathic pulmonary fibrosis (IPF) F647 (pirfenidone) from the China State...read more